Chinese Study Confirms Coronavac’s Efficacy in Phase 2 Clinical Trials

Should the vaccine be approved, technology transfer for mass production and free supply through the SUS will be ensured.

RIO DE JANEIRO, BRAZIL - The Coronavac vaccine has proven to be both effective and safe, according to a study released this week by Chinese pharmaceutical company Sinovac Life Science. The study analyzed the behavior of 600 immunized volunteers in China during phase 2 clinical trials. The vaccine is developed by Sinovac Life Science in partnership with the Butantan Institute in São Paulo.

According to the Coronavac vaccine clinical trials coordinator and the Butantan Institute Medical Director of Clinical Research, Ricardo Palácios, the product is very promising and effective. "The studies conducted thus far in China have shown that . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?